MEDICINAL USE OF ALPHA-MANNOSIDASE

The present invention provides means and strategies for treating the lysosomal storage disorder alpha-mannosidosis by enzyme replacement therapy. In particular, the invention pertains to the reduction of stored neutral mannose-rich oligosaccharides in cells within the central nervous system. Accordi...

Full description

Saved in:
Bibliographic Details
Main Authors ROCES Diego Prieto, IRANI Meher, ANDERSSON Claes, WEIGELT Cecilia, VON FIGURA Kurt, FOGH Jens
Format Patent
LanguageEnglish
Slovenian
Published 31.07.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides means and strategies for treating the lysosomal storage disorder alpha-mannosidosis by enzyme replacement therapy. In particular, the invention pertains to the reduction of stored neutral mannose-rich oligosaccharides in cells within the central nervous system. Accordingly, the present invention provides the use of a lysosomal alpha-mannosidase for the preparation of a medicament for reducing the intracellular levels of neutral mannose-rich oligosaccharides in cells within one or more regions of the central nervous system. The invention further provides a formulation of lysosomal alpha-mannosidase for use as a medicament for reducing the intracellular levels of neutral mannose-rich oligosaccharides in cells within one or more regions of the central nervous system. Also, the invention provides a method of reducing the intracellular levels of neutral mannose-rich oligosaccharides in cells within one or more regions of the central nervous system of a subject, said method comprising administering to said subject a preparation of lysosomal alpha-mannosidase. Finally, the invention pertains to methods of producing, isolating, and purifying an alpha-mannosidase as well as the use of an alpha-mannosidase, which is obtainable according to these methods.
Bibliography:Application Number: SI20050032209T